Abstract: The present invention relates to a composition for enhancing the sensitivity to a pulmonary fibrosis inhibitor, the composition comprising, as an active ingredient, stearic acid, a salt of the stearic acid or a prodrug of the stearic acid. In addition, the present invention relates to a pharmaceutical composition for preventing or treating pulmonary fibrosis, the composition comprising, as active ingredients: stearic acid, a salt of the stearic acid or a prodrug of the stearic acid; and a pulmonary fibrosis inhibitor. According to the present invention, a more excellent treatment effect may be induced by the co-administration of a conventional pulmonary fibrosis inhibitor and stearic acid, and by using stearic acid, the sensitivity to the conventional pulmonary fibrosis inhibitor may be enhanced, and an excellent treatment effect is expected to be achieved even for pulmonary fibrosis showing resistance to the conventional pulmonary fibrosis inhibitor.

Abstract: The present invention relates to a method for the toxicity assessment of nano-materials, and more specifically, it is relates to an objective, reproducible and accurate assessment method for the unbiased toxicity testings of nano-materials, which minimize artifacts of the conventional methods for the toxicity assessment of the nano-materials by considering the dose characteristics of the nano-material itself using Selective multi-Plane Illumination Microcopy (SPIM); and the response characteristics of the nano-material using the improved or novel cellular responses assessment methods for nano-materials (e.g., modified MTT assay using image cytometric analysis, normal-inverted exposure apparatus, and modified flow cytometry), and a system and an apparatus thereof.

Abstract: The present invention relates to a method for the toxicity assessment of nano-materials, and more specifically, it is relates to an objective, reproducible and accurate assessment method for the unbiased toxicity testings of nano-materials, which minimize artifacts of the conventional methods for the toxicity assessment of the nano-materials by considering the dose characteristics of the nano-material itself using Selective multi-Plane Illumination Microcopy (SPIM); and the response characteristics of the nano-material using the improved or novel cellular responses assessment methods for nano-materials (e.g., modified MTT assay using image cytometric analysis, normal-inverted exposure apparatus, and modified flow cytometry), and a system and an apparatus thereof.

Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.